Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 On the mode of action of L-deprenyl in the human central nervous system.

× No keyword cloud information.

15 in total

Review 1. Multiple forms of monoamine oxidase: fact and artefact.

Authors: M D Houslay; K F Tipton
Journal: Life Sci Date: 1976-08-15 Impact factor: 5.037

2. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors: A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal: Br J Pharmacol Date: 1977-07 Impact factor: 8.739

Review 3. Are there MAO inhibitors specific for dopamine metabolism?

Authors: M B Youdim; M Holzbauer
Journal: Adv Biochem Psychopharmacol Date: 1977

4. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors: R F Squires
Journal: Adv Biochem Psychopharmacol Date: 1972

5. Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors: J P Johnston
Journal: Biochem Pharmacol Date: 1968-07 Impact factor: 5.858

6. Multiple forms of human brain mitochondrial monoamine oxidase.

Authors: G G Collins; M Sandler; E D Williams; M B Youdim
Journal: Nature Date: 1970-02-28 Impact factor: 49.962

7. Dopamine is a monoamine oxidase B substrate in man.

Authors: V Glover; M Sandler; F Owen; G J Riley
Journal: Nature Date: 1977-01-06 Impact factor: 49.962

8. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors: W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal: Lancet Date: 1977-02-26 Impact factor: 79.321

9. Deprenyl in Parkinson's disease.

Authors: A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal: Lancet Date: 1977-10-15 Impact factor: 79.321

Review 10. Monoamine oxidase in man: enzyme characteristics in platelets, plasma, and other human tissues.

Authors: D L Murphy; C H Donnelly
Journal: Adv Biochem Psychopharmacol Date: 1974

27 in total

1. Expression of monoamine oxidase B activity in astrocytes of senile plaques.

Authors: S Nakamura; T Kawamata; I Akiguchi; M Kameyama; N Nakamura; H Kimura
Journal: Acta Neuropathol Date: 1990 Impact factor: 17.088

2. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

Authors: Ireen Denya; Sarel F Malan; Adaze B Enogieru; Sylvester I Omoruyi; Okobi E Ekpo; Erika Kapp; Frank T Zindo; Jacques Joubert
Journal: Medchemcomm Date: 2018-01-16 Impact factor: 3.597

3. Multicenter trial of L-Deprenyl in Parkinson disease.

Authors: S Ruggieri; A Denaro; G Meco; A Carta; F Stocchi; A Agnoli
Journal: Ital J Neurol Sci Date: 1986-02

Review 4. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors: Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal: J Neural Transm (Vienna) Date: 2018-02-07 Impact factor: 3.575

5. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.

Authors: J P Finberg; M Tenne
Journal: Br J Pharmacol Date: 1982-09 Impact factor: 8.739

6. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors: M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal: Neurochem Res Date: 1998-08 Impact factor: 3.996

7. Absence of "cheese effect" during deprenyl therapy: some recent studies.

Authors: M Sandler; V Glover; A Ashford; G M Stern
Journal: J Neural Transm Date: 1978 Impact factor: 3.575

Review 8. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors: M B Youdim; P Riederer
Journal: J Neural Transm Gen Sect Date: 1993

Review 9. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors: P Chrisp; G J Mammen; E M Sorkin
Journal: Drugs Aging Date: 1991-05 Impact factor: 3.923

10. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Authors: Orly Weinreb; Tamar Amit; Yotam Sagi; Noam Drigues; Moussa B H Youdim
Journal: J Neural Transm (Vienna) Date: 2009-04-25 Impact factor: 3.575